Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Lipiodol visibility under ultrasound.

Zen M, Kirby A, Dowthwaite S, Gibson R, Mizia K.

Aust N Z J Obstet Gynaecol. 2020 Mar 23. doi: 10.1111/ajo.13150. [Epub ahead of print]

PMID:
32207160
2.

Preclinical and early systemic lupus erythematosus.

Gatto M, Saccon F, Zen M, Iaccarino L, Doria A.

Best Pract Res Clin Rheumatol. 2019 Aug;33(4):101422. doi: 10.1016/j.berh.2019.06.004. Epub 2019 Jul 12. Review.

PMID:
31810542
3.

Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.

Zen M, Saccon F, Gatto M, Montesso G, Larosa M, Benvenuti F, Iaccarino L, Doria A.

Rheumatology (Oxford). 2019 Oct 23. pii: kez422. doi: 10.1093/rheumatology/kez422. [Epub ahead of print]

PMID:
31642908
4.

Urinary and Serum Angiogenic Markers in Women With Preexisting Diabetes During Pregnancy and Their Role in Preeclampsia Prediction.

Zen M, Padmanabhan S, Zhang K, Kirby A, Cheung NW, Lee VW, Alahakoon TI.

Diabetes Care. 2020 Jan;43(1):67-73. doi: 10.2337/dc19-0967. Epub 2019 Oct 10.

PMID:
31601637
5.

Response to: 'Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population', by Rodríguez-González et al.

Jesus D, Matos A, Henriques C, Zen M, Doria A, Inês LS.

Ann Rheum Dis. 2019 Aug 7. pii: annrheumdis-2019-216110. doi: 10.1136/annrheumdis-2019-216110. [Epub ahead of print] No abstract available.

PMID:
31391180
6.

Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?

Zhang K, Zen M, Popovic NL, Lee VW, Alahakoon TI.

J Obstet Gynaecol Res. 2019 Sep;45(9):1828-1836. doi: 10.1111/jog.14038. Epub 2019 Jul 1.

PMID:
31257726
7.

Response to: 'SLE-DAS: ready for routine use' by Mathew et al.

Jesus D, Matos A, Henriques C, Zen M, Doria A, Inês LS.

Ann Rheum Dis. 2019 Jun 14. pii: annrheumdis-2019-215794. doi: 10.1136/annrheumdis-2019-215794. [Epub ahead of print] No abstract available.

PMID:
31201172
8.

Response to: 'Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort', by Hassan et al.

Jesus D, Zen M, Doria A, Inês LS.

Ann Rheum Dis. 2019 Apr 25. pii: annrheumdis-2019-215430. doi: 10.1136/annrheumdis-2019-215430. [Epub ahead of print] No abstract available.

PMID:
31023656
9.

Undifferentiated connective tissue disease: state of the art on clinical practice guidelines.

Antunes M, Scirè CA, Talarico R, Alexander T, Avcin T, Belocchi C, Doria A, Franceschini F, Galetti I, Govoni M, Hachulla E, Launay D, Lepri G, Macieira C, Matucci-Cerinic M, Montecucco CM, Moraes-Fontes MF, Mouthon L, Paolino S, Ramoni V, Tani C, Tas SW, Tincani A, Van Vollenhoven R, Zen M, Fonseca J, Bombardieri S, Fonseca JE, Schneider M, Smith V, Cutolo M, Mosca M, Beretta L.

RMD Open. 2019 Feb 26;4(Suppl 1):e000786. doi: 10.1136/rmdopen-2018-000786. eCollection 2018. Review.

10.

Microalbuminuria as an early predictor of preeclampsia in the pre-gestational diabetic population: A prospective cohort study.

Zen M, Padmanabhan S, Cheung NW, Kirby A, Jesudason S, Alahakoon TI, Lee VW.

Pregnancy Hypertens. 2019 Jan;15:182-188. doi: 10.1016/j.preghy.2019.01.010. Epub 2019 Jan 28.

PMID:
30825920
11.

Upscaling ecosystem service maps to administrative levels: beyond scale mismatches.

Zen M, Candiago S, Schirpke U, Egarter Vigl L, Giupponi C.

Sci Total Environ. 2019 Apr 10;660:1565-1575. doi: 10.1016/j.scitotenv.2019.01.087. Epub 2019 Jan 9.

12.

IL-12 and IL-23/Th17 axis in systemic lupus erythematosus.

Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, Inês L, Doria A.

Exp Biol Med (Maywood). 2019 Jan;244(1):42-51. doi: 10.1177/1535370218824547. Epub 2019 Jan 21.

13.

Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.

Jesus D, Matos A, Henriques C, Zen M, Larosa M, Iaccarino L, Da Silva JAP, Doria A, Inês LS.

Ann Rheum Dis. 2019 Mar;78(3):365-371. doi: 10.1136/annrheumdis-2018-214502. Epub 2019 Jan 9.

PMID:
30626657
14.

New therapeutic strategies in systemic lupus erythematosus management.

Gatto M, Zen M, Iaccarino L, Doria A.

Nat Rev Rheumatol. 2019 Jan;15(1):30-48. doi: 10.1038/s41584-018-0133-2. Review.

PMID:
30538302
15.

Diagnostic and prognostic role of renal histopathology in rheumatic diseases.

Saccon F, Gatto M, Larosa M, Ometto F, Felicetti M, Padoan R, Zen M.

Reumatismo. 2018 Oct 3;70(3):165-177. doi: 10.4081/reumatismo.2018.1064. Review.

16.

Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.

Trentin F, Gatto M, Zen M, Larosa M, Nalotto L, Saccon F, Zanatta E, Iaccarino L, Doria A.

Clin Rev Allergy Immunol. 2018 Oct;55(2):237. doi: 10.1007/s12016-018-8704-1.

17.

Underage victims and perpetrators of murder in Italy: 2007-2015.

Terranova C, Zen M, Maguolo N, Cirillo T, Montisci M.

J Forensic Leg Med. 2018 Oct;59:39-44. doi: 10.1016/j.jflm.2018.08.002. Epub 2018 Aug 14.

PMID:
30130701
18.

Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis.

Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, Raffiotta F, Zen M, Costantini G, Urban ML, Pieruzzi F, Messa P, Vaglio A, Sinico RA, Doria A.

Ann Rheum Dis. 2018 Sep;77(9):1318-1325. doi: 10.1136/annrheumdis-2017-212732. Epub 2018 May 5.

PMID:
29730634
19.

Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.

Trentin F, Gatto M, Zen M, Larosa M, Maddalena L, Nalotto L, Saccon F, Zanatta E, Iaccarino L, Doria A.

Clin Rev Allergy Immunol. 2018 Apr;54(2):331-343. doi: 10.1007/s12016-018-8675-2. Review. Erratum in: Clin Rev Allergy Immunol. 2018 Oct;55(2):237. Maddalena L [corrected to Larosa M ].

20.

Response to: 'Remission or low disease activity as a target in systemic lupus erythematosus' by Ugarte-Gil et al.

Zen M, Doria A.

Ann Rheum Dis. 2019 Jan;78(1):e4. doi: 10.1136/annrheumdis-2017-212911. Epub 2018 Jan 17. No abstract available.

PMID:
29343511
21.

Women victims of intentional homicide in Italy: New insights comparing Italian trends to German and U.S. trends, 2008-2014.

Terranova C, Zen M.

J Forensic Leg Med. 2018 Jan;53:73-78. doi: 10.1016/j.jflm.2017.11.007. Epub 2017 Nov 28.

PMID:
29202317
22.

Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.

Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, Punzi L, Doria A.

Ann Rheum Dis. 2018 Jan;77(1):104-110. doi: 10.1136/annrheumdis-2017-211613. Epub 2017 Sep 26.

PMID:
28970217
23.

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.

Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F, De Angelis R, De Marchi G, De Vita S, Di Matteo A, Emmi G, Emmi L, Gatto M, Gerli R, Gerosa M, Govoni M, Larosa M, Meroni PL, Mosca M, Pazzola G, Reggia R, Saccon F, Salvarani C, Tani C, Zen M, Frigo AC, Tincani A, Doria A.

J Autoimmun. 2018 Jan;86:1-8. doi: 10.1016/j.jaut.2017.09.004. Epub 2017 Sep 19.

PMID:
28935492
24.

The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission.

Zen M, Gatto M, Nalotto L, Larosa M, Iaccarino L, Doria A.

Isr Med Assoc J. 2017 Jul;19(7):454-458. Review. No abstract available.

25.

Crimes against the elderly in Italy, 2007-2014.

Terranova C, Bevilacqua G, Zen M, Montisci M.

J Forensic Leg Med. 2017 Aug;50:20-27. doi: 10.1016/j.jflm.2017.06.005. Epub 2017 Jun 27.

PMID:
28683406
26.

When to use belimumab in SLE.

Gatto M, Iaccarino L, Zen M, Doria A.

Expert Rev Clin Immunol. 2017 Aug;13(8):737-740. doi: 10.1080/1744666X.2017.1324784. Epub 2017 May 5. No abstract available.

PMID:
28463023
27.

Glucuronidation: driving factors and their impact on glucuronide disposition.

Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J, Shi J, Zhu L, Liu Z, Wang Y, Gao S, Hu M.

Drug Metab Rev. 2017 May;49(2):105-138. doi: 10.1080/03602532.2017.1293682. Epub 2017 May 22. Review.

PMID:
28266877
28.

The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients.

Zen M, Iaccarino L, Gatto M, Bettio S, Saccon F, Ghirardello A, Punzi L, Doria A.

Ann Rheum Dis. 2017 Mar;76(3):562-565. doi: 10.1136/annrheumdis-2016-210154. Epub 2016 Nov 24.

PMID:
27884821
29.

Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study.

Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, Zaina B, Tincani A, de Liso F, Matinato C, Grossi C, Gatto M, Castellana P, Limardo M, Meroni PL, Messa P, Ravani P, Mosca M.

J Autoimmun. 2016 Nov;74:6-12. doi: 10.1016/j.jaut.2016.07.010. Epub 2016 Aug 2.

PMID:
27496151
30.

Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis.

Gatto M, Saccon F, Zen M, Bettio S, Iaccarino L, Punzi L, Doria A.

J Autoimmun. 2016 Nov;74:94-105. doi: 10.1016/j.jaut.2016.06.014. Epub 2016 Jun 30. Review.

PMID:
27373904
31.

Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study.

Moroni G, Doria A, Giglio E, Imbasciati E, Tani C, Zen M, Strigini F, Zaina B, Tincani A, Gatto M, de Liso F, Grossi C, Meroni PL, Cabiddu G, Messa P, Ravani P, Mosca M.

J Autoimmun. 2016 Nov;74:194-200. doi: 10.1016/j.jaut.2016.06.012. Epub 2016 Jun 30.

PMID:
27373903
32.

Remission in SLE: the duration depends on multiple factors, including the definition.

Doria A, Zen M, Iaccarino L.

Ann Rheum Dis. 2016 Dec;75(12):e77. doi: 10.1136/annrheumdis-2016-210502. Epub 2016 Oct 5. No abstract available.

PMID:
27707731
33.

Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.

Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.

Arthritis Care Res (Hoboken). 2017 Jan;69(1):115-123. doi: 10.1002/acr.22971. Epub 2016 Nov 18.

34.

Pre-existing diabetes in pregnancy.

Padmanabhan S, Zen M, Lee V, Cheung NW.

Minerva Endocrinol. 2016 Mar;41(1):122-37. Review.

PMID:
26878562
35.

Pre-existing diabetes in pregnancy.

Padmanabhan S, Zen M, Lee V, Cheung NW.

Minerva Endocrinol. 2016 Jan 14. [Epub ahead of print]

PMID:
26765067
36.

Prolonged remission in Caucasian patients with SLE: prevalence and outcomes.

Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, Punzi L, Doria A.

Ann Rheum Dis. 2015 Dec;74(12):2117-22. doi: 10.1136/annrheumdis-2015-207347. Epub 2015 Jul 29.

PMID:
26223434
37.

Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.

Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, Ferraccioli G, Galeazzi M, Gatto M, Gerli R, Govoni M, Gremese E, Iuliano A, Mansutti E, Moroni G, Mosca M, Nalli C, Naretto C, Padovan M, Palma L, Raffiotta F, Roccatello D, Tincani A, Valesini G, Zen M, Doria A.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4):449-56. Epub 2015 Jun 8.

PMID:
26053285
38.

Drugs in induction and treatment of idiopathic inflammatory myopathies.

Iaccarino L, Bartoloni E, Gerli R, Alunno A, Barsotti S, Cafaro G, Gatto M, Talarico R, Tripoli A, Zen M, Neri R, Doria A.

Auto Immun Highlights. 2014 Oct 19;5(3):95-100. doi: 10.1007/s13317-014-0065-z. eCollection 2014 Dec. Review.

39.

PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis.

Bassi N, Del Prete D, Ghirardello A, Gatto M, Ceol M, Zen M, Bettio S, Mantovani A, Iaccarino L, Punzi L, Doria A.

Clin Rev Allergy Immunol. 2015 Oct;49(2):217-26. doi: 10.1007/s12016-015-8476-9.

PMID:
25805362
40.

The body against self: autoinflammation and autoimmunity.

Borella E, Palma L, Zen M, Bettio S, Nalotto L, Gatto M, Domeneghetti M, Laccarino L, Punzi L, Doria A.

Isr Med Assoc J. 2014 Oct;16(10):608-10. No abstract available.

41.

The olfactory function is impaired in patients with idiopathic inflammatory myopathies.

Iaccarino L, Shoenfeld N, Rampudda M, Zen M, Gatto M, Ghirardello A, Bassi N, Punzi L, Shoenfeld Y, Doria A.

Immunol Res. 2014 Dec;60(2-3):247-52. doi: 10.1007/s12026-014-8581-5.

PMID:
25391613
42.

Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus.

Bortoluzzi A, Scirè CA, Bombardieri S, Caniatti L, Conti F, De Vita S, Doria A, Ferraccioli G, Gremese E, Mansutti E, Mathieu A, Mosca M, Padovan M, Piga M, Tincani A, Tola MR, Tomietto P, Valesini G, Zen M, Govoni M; Study Group on Neuropsychiatric Systemic Lupus Erythematosus of the Italian Society of Rheumatology.

Rheumatology (Oxford). 2015 May;54(5):891-8. doi: 10.1093/rheumatology/keu384. Epub 2014 Oct 21. Review.

PMID:
25339643
43.

Optimizing outcome in SLE: treating-to-target and definition of treatment goals.

Doria A, Gatto M, Zen M, Iaccarino L, Punzi L.

Autoimmun Rev. 2014 Jul;13(7):770-7. doi: 10.1016/j.autrev.2014.01.055. Epub 2014 Jan 27. Review.

PMID:
24480071
44.

The clinical features, diagnosis and classification of dermatomyositis.

Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, Doria A.

J Autoimmun. 2014 Feb-Mar;48-49:122-7. doi: 10.1016/j.jaut.2013.11.005. Epub 2014 Jan 24. Review.

PMID:
24467910
45.

Premature coronary heart disease in SLE: can we prevent progression?

Iaccarino L, Bettio S, Zen M, Nalotto L, Gatto M, Ramonda R, Punzi L, Doria A.

Lupus. 2013 Oct;22(12):1232-42. doi: 10.1177/0961203313492871.

PMID:
24097995
46.

Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease.

Villalta D, Bizzaro N, Bassi N, Zen M, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A.

PLoS One. 2013 Aug 12;8(8):e71458. doi: 10.1371/journal.pone.0071458. eCollection 2013.

47.

Ethical and medico-legal implications of capacity of patients in geriatric surgery.

Terranova C, Cardin F, Pietra LD, Zen M, Bruttocao A, Militello C.

Med Sci Law. 2013 Jul;53(3):166-71. doi: 10.1177/0025802412473963. Epub 2013 Jul 10.

PMID:
23842478
48.

Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.

Nalotto L, Iaccarino L, Zen M, Gatto M, Borella E, Domenighetti M, Punzi L, Doria A.

Immunol Res. 2013 Jul;56(2-3):362-70. doi: 10.1007/s12026-013-8408-9. Review.

PMID:
23572427
49.

Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review.

Zen M, Gatto M, Domeneghetti M, Palma L, Borella E, Iaccarino L, Punzi L, Doria A.

Clin Rev Allergy Immunol. 2013 Oct;45(2):227-35. doi: 10.1007/s12016-013-8355-1. Review.

PMID:
23322404
50.

Polarization of TH2 response is decreased during pregnancy in systemic lupus erythematosus.

Iaccarino L, Ghirardello A, Zen M, Villalta D, Tincani A, Punzi L, Doria A.

Reumatismo. 2012 Dec 11;64(5):314-20. doi: 10.4081/reumatismo.2012.314.

PMID:
23256107

Supplemental Content

Support Center